Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 7/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL936420 | 0.86 | PDE2A (0.62) | PDE2AHSD17B10GRIN2DGRIN3BGRIN1 | |
| SCHEMBL2680388 | 0.78 | PDE2A (0.54) | PDE2AHSD17B10GRIN2DGRIN3BGRIN1 | |
| SCHEMBL1003413 | 0.77 | PDE2A (1.00) | PDE2AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL935062 | 0.74 | PDE2A (0.51) | PDE2AHSD17B10TYMPCDK5CDK5R1 | |
| SCHEMBL1082259 | 0.74 | PDE2A (0.76) | PDE2AHSD17B10GRIN2DGRIN3BGRIN1 | |
| SCHEMBL936369 | 0.73 | PDE2A (0.91) | PDE2AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL959320 | 0.72 | PDE2A (0.85) | PDE2AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL935992 | 0.72 | PDE2A (0.51) | PDE2AHSD17B10GRIN2DGRIN3BGRIN1 | |
| SCHEMBL1082751 | 0.72 | PDE2A (0.73) | PDE2AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL2681578 | 0.72 | PDE2A (0.83) | PDE2AGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2456440-B1 | QUINOLINONE PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2015-08-19 | — | — | EP | claimed |
| US-8680116-B2 | Quinolinone PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-25 | — | — | US | claimed |
| EP-2456440-A1 | QUINOLINONE PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-05-30 | — | — | EP | claimed |
| US-20120115885-A1 | Quinolinone PDE2 Inhibitors | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | claimed |
| WO-2011011312-A1 | QUINOLINONE PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-01-27 | — | — | WO | claimed |
| EP-2456440-B1 | QUINOLINONE PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2015-08-19 | — | — | EP | disclosed |
| EP-2456440-B1 | QUINOLINONE PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2015-08-19 | — | — | EP | disclosed |
| US-8680116-B2 | Quinolinone PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680116-B2 | Quinolinone PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680116-B2 | Quinolinone PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120115885-A1 | Quinolinone PDE2 Inhibitors | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120115885-A1 | Quinolinone PDE2 Inhibitors | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120115885-A1 | Quinolinone PDE2 Inhibitors | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| WO-2011011312-A1 | QUINOLINONE PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115885-A1 | Quinolinone PDE2 Inhibitors | PDE12, PDE2A, PDE4A | PDE2A 2/4885HSD17B10 403/4885GRIN2D 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.